Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Orthopedics Inflammation

PriceSpective appoints Bob Nordyke to lead new unit

This article was originally published in Scrip

  • Zoë Dann

Executive Summary

PriceSpective, a consultancy providing pricing and reimbursement services to pharmaceutical, biotechnology and healthcare companies, has appointed Bob Nordyke to lead its new Health Economics and Outcomes Research (HEOR) practice. He has more than 18 years' HEOR experience, having previously worked as part of the global health economics team at Amgen where he served in various roles, including therapeutic area head for inflammation, global payer lead and global health economics lead for haematology/oncology and programme lead for EMR-based registry capability for oncology. Before Amgen, Mr Nordyke was director of outcomes research at Cerner LifeSciences and a research fellow at the RAND Corporation.

Table

View full table

Topics

Related Companies

Tags:
Orthopedics Inflammation
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC008377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By